Using modified stem cells to fight HIV infection
HIV Reservoir and Gene Modified Cell Dynamics Following Autologous Stem Cell Transplantation
This study is looking at a new treatment that uses specially modified cells from your own body to help fight HIV and reduce the virus in people who are getting stem cell transplants, and it aims to make this treatment safer and more effective for you.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project ID | NIH-10992648 on NIH RePORTER |
What this research studies
This research investigates the use of autologous gene-modified cells that are resistant to HIV to reduce the viral reservoir in patients. The approach combines multiple anti-HIV genes into a single lentiviral vector, which aims to block HIV infection at various stages of its life cycle. By focusing on a more comprehensive strategy than current methods, this research seeks to provide a stronger defense against HIV for individuals undergoing autologous stem cell transplantation. Patients who participate will be monitored for safety and effectiveness of this innovative treatment.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals living with HIV who require autologous stem cell transplantation, particularly those with lymphoma.
Not a fit: Patients who are not living with HIV or those who do not require stem cell transplantation may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a significant reduction in HIV viral load and potentially allow patients to control the virus without ongoing antiretroviral therapy.
How similar studies have performed: Previous studies have shown promise in using gene-modified cells for HIV treatment, indicating that this approach could be a significant advancement in HIV therapy.
Where this research is happening
San Francisco, United States
- University of California, San Francisco — San Francisco, United States (Active)
Researchers
- Principal investigator: Henrich, Timothy Jensen — University of California, San Francisco
- Study coordinator: Henrich, Timothy Jensen
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.